RAISING THE BAR FOR BETTER OUTCOMES IN NSCLC

PROGRAM

18:15-18:25  Welcome and introduction: preparing for the future of NSCLC treatment
Alastair Greystoke (UK) (Chair)

18:25-18:50  Tumor-promoting inflammation: the emerging role of IL-1β in NSCLC
Martin Reck (Germany)

18:50-19:10  Novel oncogenic drivers: addressing the remaining unMET needs
Egbert Smit (Netherlands)

19:10-19:15  Meeting closure
Alastair Greystoke (UK) (Chair)

This scientific meeting may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or material was developed for use outside of the USA, is intended for non-US HCPs, and is to be used in accordance with local laws and regulations.